Prostate cancer detection rate of 16-core TRUS-guided prostate biopsy in Rajavithi Hospital
DOI:
https://doi.org/10.52786/isu.a.98Keywords:
Biopsy, prostate, prostate cancer, 16-cores, trans rectal ultrasound prostate biopsyAbstract
Objective: Prostate cancer is one of the most prevalent malignancies in the male Thai population. Early detection of prostate cancer increases the chance of organ confined and potentially curable disease. To date, the grayscale transrectal ultrasound (TRUS) is a common modality for prostate diagnosis and the extended 12-core biopsy is con- sidered adequate for cancer detection. With the aim of increasing the peripheral zone of prostate biopsy sampling, Rajavithi Hospital performed a 16-core TRUS-guided prostate biopsy instead. The objectives of this study are to evaluate the rate of prostate cancer detection and to review the factors associated in 16-core TRUS-guided prostate biopsy in Rajavithi Hospital.
Materials and Methods: TRUS-guided prostate biopsy was performed in 243 patients between October 2019 and September 2021 in Rajavithi Hospital. Using retrospective methods, 200 patients were included in this study. The factors associated with prostate cancer detection were analyzed by independent sample t-test, Mann-Whitney U test, Chi-square test and Fisher’s exact test, and Multiple logistic regression methods.
Results: The average age of TRUS-guided prostate biopsy patient in Rajavithi Hospital was 69.28 ± 8.41 years. Prostate cancer was detected in 70 patients (35.0%). Factors significantly associated with a positive diagnosis were: abnormal digital rectal exam (DRE) (74.3%, p < 0.001), PSA level > 10 ng/ml (mean 9.87 ng/ml, p < 0.001), and PSAD ≥ 15 ng/ml/g (94.3%, p < 0.001). Among prostate cancer patients, in the majority of cases the positive tissue was found at lateral core (31.0%), followed by the apical core (28.5%), medial core (27.5%) and anterior core (23.5%). No factors were found to be related to increasing prostate cancer detection tissue in the lateral core with the exception of abnormal DRE.
Conclusion: A 16-core TRUS-guided prostate biopsy may be useful for the detec- tion of prostate cancer in patients with abnormal DRE, high PSA, and high PSAD.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
Permpongkosol S. Prostate cancer statistics in Thailand [Internet]. [cited 2023 Jan 1]. Prostate Cancer in Ramathibodi Hospital 2014. Available from: https:// www.rama.mahidol.ac.th/cancer_center/th/news/ event/15062016-1529-th
Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659- 64.
Schröder F, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012;62:745-52.
Trabulsi EJ, Halpern EJ, Gomella LG. Prostate biopsy: techniques and imaging. In: Partin AW, Dmochoski RR, Kavoussi LR, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier Saunders; 2020. p. 3490.
Hodge K, McNeal J, Terris M, Stamey T. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71-4.
Presti J, Chang J, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: J Urol 2000;163:163-6;discussion 166-7.
Bjurlin M, Carter H, Schellhammer P, Cookson M, Gomella L, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 2013;189:2039-46.
McNeal J, Redwine E, Freiha F, Stamey T. Zonal distribution of prostatic adenocarcinoma. Am J Surg Pathol 1988;12:897-906.
Byar D, Mostofi F. Carcinoma of the prostate: Prog- nostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer 1972;30:5-13.
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
McNeal J. Origin and development of carcinoma in the prostate. Cancer 1969;23:24-34.
Chang J, Shinohara K, Bhargava V, Presti J. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998;160:2111-14.
Miyoshi Y, Furuya M, Teranishi J, Noguchi K, Uemura H, Yokomizo Y, et al. Comparison of 12- and 16-core prostate biopsy in japanese patients with serum prostate-specific antigen level of 4.0-20.0 ng/mL. Urol J 2014;11:1609-14.
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate
cancer: AUA Guideline. J Urol 2013;190:419-26.
Carrol PR, Parsons JK, Bahnson RR, Carlsson S, Castie EP, Catalona WJ, et al. NCCN Guidelines Version 2.2019 Prostate Cancer Early Detection [Internet]. 2019 [cited 2022 August 7]. Available from: https://www2.trikobe.org/nccn/guideline/urological/english/prostate_detection.pdf
Trabulsi EJ, Halpern EJ, Gomella LG. Prostate Biopsy: Techniques and Imaging. In: Partin AW, Dmochoski RR, Kavoussi LR, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier Saunders; 2020. p. 3495.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Insight Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
